Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer

Conditions:   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Infection;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms;   Precancerous Condition;   Secondary Myelofibrosis;   Small Intestine CancerInterventions:   Biological: anti-thymocyte globulin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: fludarabine phosphate;   Drug: melphalan;   Drug: methotrexate;   Drug: sirolimus;   Drug: tacrolimus;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: hematopoietic stem cell transplantation;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: total-body irradiationSponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)Completed - verified September 2014
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials